Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Noah L. Rosenberg
Institution:
Pontifícia Universidade Católica do Paraná
Observed institutions:
Pontifícia Universidade Católica do Paraná,
Esperion Therapeutics (United States)
OpenAlex ID:
A5108428765
Efficacy and Safety of a Novel Dual Modulator of Adenosine Triphosphate-Citrate Lyase and Adenosine Monophosphate-Activated Protein Kinase in Patients With Hypercholesterolemia
2013
·
Christie M. Ballantyne
, Michael H. Davidson
, et al.
·
Journal of the American College of Cardiology
·
188
PDF
Efficacy and Safety of ETC-1002, a Novel Investigational Low-Density Lipoprotein-Cholesterol–Lowering Therapy for the Treatment of Patients With Hypercholesterolemia and Type 2 Diabetes Mellitus
2014
·
Maria J. Gutierrez
, Noah L. Rosenberg
, et al.
·
Arteriosclerosis Thrombosis and Vascular Biology
·
176
International consensus definitions of clinical trial outcomes for kidney failure: 2020
2020
·
Adeera Levin
, Rajiv Agarwal
, et al.
·
Kidney International
·
133
PDF
ETC-1002 Lowers LDL-Cholesterol and is Well Tolerated in Hypercholesterolemic Patients Across Four Phase 2a Studies
2014
·
Roger S. Newton
, Christie M. Ballantyne
, et al.
·
Journal of clinical lipidology
·
6
ETC-1002 Lowers LDL-Cholesterol and is Well Tolerated in Hypercholesterolemic Patients with Statin Intolerance†
2014
·
Roger S. Newton
, Paul Davis Thompson
, et al.
·
Journal of clinical lipidology
·
3
ETC-1002 Reduces Blood Pressure in Hypercholesterolemic Patients with Mildly Elevated Blood Pressure
2014
·
Roger S. Newton
, Diane E. MacDougall
, et al.
·
Journal of clinical lipidology
Show more works
View as search
Works count:
6
Citation count:
506
H-index:
4
I10-index:
3
Year
Topic
Type